To determine the diagnostic utility of plasma biomarkers (GFAP, UCH-L1, NfL, and BD-tau) in older adults presenting to an emergency department within 72 hours of injury.
Key Findings:
Older adults experience higher incidence of TBI-related hospitalizations and deaths, highlighting the need for improved diagnostic methods.
Diagnostic criteria for mTBI are challenging due to subjective and nonspecific symptoms, complicating clinical decision-making.
Blood-based biomarkers like GFAP and NfL may improve diagnostic accuracy for mTBI, potentially leading to better patient outcomes.
Interpretation:
The study aims to address the diagnostic gray zone in older adults with suspected mTBI by evaluating the utility of plasma biomarkers, which could enhance diagnostic precision.
Limitations:
The study is limited to a single center, which may affect generalizability to broader populations.
Exclusion criteria may limit the diversity of the sample, potentially impacting the applicability of findings.
Conclusion:
The study seeks to validate the use of plasma biomarkers in diagnosing mTBI in older adults, particularly in cases lacking definitive clinical signs, which could significantly influence clinical practice.
by Gershon Spitz, Jake Mitchell, Beatrice Duarte Martins, Abigail Astridge, Charlotte Copas, William T. O’Brien, Georgia F. Symons, Meng Law, Terence J. O’Brien, Matthew P. Pase, Jennie L. Ponsford, Biswadev Mitra, Stuart J. McDonald, Sandy R. Shultz
